News

Company   ImmuPharma PLC
TIDM         IMM
Headline    AGM and Board Update
Released    14:00 13-Jun-07
Number     2954Y

FOR IMMEDIATE RELEASE

London, 13 June 2007

AGM Statement and Board Update

ImmuPharma plc (LSE:IMM), the specialist pharmaceutical discovery and development company, held its AGM earlier today and is pleased to
announce that all resolutions were passed.

Paddy Walker-Taylor, 60, currently part-time finance director, has decided by mutual agreement with the company to resign his role as director but remain with the company on a reduced-time basis.

The Board wishes to thank Mr Walker-Taylor for his support during the early phase of the company and look forward to continuing working together.

Dr. Robert Zimmer, MD, PhD, President & head of R&D, said "we are delighted with the achievements in our R&D activities and in particular, the progress in the preparation of the phase II/III in the US and Europe, for which we hope to submit the file to the FDA in the next few weeks with the view of starting the phase II/III trial later this year."

For further information please contact:

ImmuPharma PLC

Dimitri Dimitriou, Chief Executive Officer                         +44 20 7152 4080
Richard Warr, Chairman                                                +44 20 7152 4080
Dr Robert Zimmer, President & Chief                              +33 389 32 76 50
Scientific Officer

Buchanan Communications +44 20 7466 5000

Lisa Baderoon
Rebecca Skye-Dietrich


Home About ImmuPharma Lead compounds Discovery pipeline Management team News For Investors Contact us	News Company ImmuPharma PLC TIDM IMM Headline AGM and Board Update Released 14:00 13-Jun-07 Number 2954Y FOR IMMEDIATE RELEASE London, 13 June 2007 AGM Statement and Board Update ImmuPharma plc (LSE:IMM), the specialist pharmaceutical discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were passed. Paddy Walker-Taylor, 60, currently part-time finance director, has decided by mutual agreement with the company to resign his role as director but remain with the company on a reduced-time basis. The Board wishes to thank Mr Walker-Taylor for his support during the early phase of the company and look forward to continuing working together. Dr. Robert Zimmer, MD, PhD, President & head of R&D, said "we are delighted with the achievements in our R&D activities and in particular, the progress in the preparation of the phase II/III in the US and Europe, for which we hope to submit the file to the FDA in the next few weeks with the view of starting the phase II/III trial later this year." For further information please contact: ImmuPharma PLC Dimitri Dimitriou, Chief Executive Officer +44 20 7152 4080 Richard Warr, Chairman +44 20 7152 4080 Dr Robert Zimmer, President & Chief +33 389 32 76 50 Scientific Officer Buchanan Communications +44 20 7466 5000 Lisa Baderoon Rebecca Skye-Dietrich